Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dobutamine in Septic Cardiomyopathy (ADAPT)
NCT04166331Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Sep 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dobutamine in septic shock, septic cardiomyopathy (SCM), sponsored by CHU de Limoges. Started Sep 2020; status: completed.
02
Drugs
dobutamine
03
Conditions
septic shockseptic cardiomyopathy (SCM)
Beyond the preview
Go deeper on NCT04166331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166331.